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Abstract
Background: Whether a delay in 
the initiation of chemotherapy for 
advanced non-small cell lung cancer 
(NSCLC) can affect overall survival is 
not well studied. We aim to evaluate 
the effect of the time interval between 
diagnosis and initiation of 
chemotherapy on overall survival in 
patients with stage IV NSCLC.
Methods: A retrospective review 
of newly diagnosed stage IV NSCLC 
patients who received chemotherapy 
between 1995 and 2012 was conducted. 
Demographics, histology and site(s) of 
metastases of patients were reviewed. 
Time interval between the date of 
diagnosis and the date of starting 
chemotherapy was calculated in days. 
Patients were divided in two groups 
based on median time interval: Group 
A < 46 days and group B > 46 days. 
The primary end point was the 
difference in overall survival between 
the two groups.
Results: A total of 172 patients 
were reviewed. Each group had 86 
patients. Median age for both groups 
was 61 years. The most common 
histology was adenocarcinoma in A 
and B (43% vs. 45%, respectively). The 
sites of metastases in A and B were: 
brain (25% vs. 28%), liver (20% vs. 9%), 
bone (30% vs. 30%), respectively. 
Performance status of ECOG (Eastern 
Cooperative Oncology Group) :( 0-1) 
was 82% vs. 76% in A and B, 
respectively. The median overall 
survival for A was 7 months vs.12 
months for B (p=0.04). 
Conclusion: In this single 
institution review, delayed 
chemotherapy for stage IV NSCLC 
more than 46 days did not have a 
detrimental effect on overall survival 
and even suggested a better outcome. 
Further larger and prospective studies 
are warranted to validate these 
findings.
Introduction
Lung cancer is the leading cause 
of cancer related death for both men 
and women with 228,190 new cases 
of lung cancer and 159,480 deaths 
estimated in 2013 in the United 
States.1,2 The majority of newly 
diagnosed lung cancers have a 
non–small-cell lung cancer (NSCLC) 
histological type accounting for 
85% of lung malignancies.3 
The 5- year overall survival of 
all stages of NSCLCs is 14 %.4 
The intent of treatment in NSCLC 
is stage dependent. Stages I, II 
and III are treated with curative 
intent with either surgical resection, 
radiotherapy, chemotherapy or 
combined modalities; whereas 
stage IV NSCLC is considered as 
an incurable disease and treated 
with palliative intent with systemic 
chemotherapy. The prognosis of 
stage IV disease remains poor. In a 
SEER (Surveillance, Epidemiology, 
and End Results) data base review, 
stage IV NSCLC had median 
survival of only 4 months.5
Although recent advances in 
targeted therapy have improved 
survival outcome for select 
patients with stage IV NSCLC 
who have EGFR mutations and 
ALK gene-rearrangement,6, 7 
systemic chemotherapy remains 
the mainstay of treatment in the 
majority of patients with stage IV 
disease with modest improvement 
in survival for tumors who are not 
candidates for targeted agents.8
The effect of delayed 
chemotherapy had been studied 
in colon and breast cancer.9,10 
In a meta-analysis, the delay of 
adjuvant chemotherapy of more 
than 8 weeks for colon cancer was 
associated with an inferior outcome.9 
In breast cancer, delayed adjuvant 
chemotherapy after 12 weeks 
negatively affects the progression 
free and overall survival.10
The data evaluating the effect of 
delaying chemotherapy in stage 
IV lung cancer is limited. In the 
adjuvant setting, a retrospective 
report from Ontario Canada revealed 
that time between surgery and 
initiation of chemotherapy in NSCLC 
of more than 10 weeks did not 
affect the outcome.11 A single center 
retrospective study by Bozcuk et al 
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reported that the time to treatment 
for all stages of NSCLC did not 
affect the survival at any stage.12 
To evaluate the impact of delaying 
systemic chemotherapy on overall 
survival mainly in stage IV NSCLC, 
we conducted a retrospective 
review of all stage IV NSCLC 
patients seen in our institution.
Methods
We conducted a retrospective 
review of the tumor registry records 
of newly diagnosed Stage IV NSCLC 
patients who received chemotherapy 
between 1995 and 2012 at Cabell 
Huntington Hospital, WV. The study 
was approved by Marshall University 
IRB. A total of 357 patients with 
stage IV pathologically confirmed 
NSCLC was identified. Patients 
with lung metastases from other 
primary malignancies, those with 
small cell carcinoma of the lung, 
those who declined therapy or 
those with no documented date 
of starting therapy were excluded. 
Age at diagnosis, race, sex, 
histology, sites of metastases, 
date of diagnosis, performance 
status and date of chemotherapy 
initiation were collected. 
The time interval was defined as 
the number of days between the 
date of diagnosis and the date of 
starting systemic chemotherapy. 
Patients were divided into 2 groups 
based on the median time interval: 
early treatment group with time 
interval less than 46 days (group 
A), and delayed treatment group 
with time interval equal to or more 
than 46 days (group B). The primary 
end point was the median overall 
survival between the two groups.
Results
Out of 357 patients, 172 patients 
were analyzed with known dates of 
diagnosis and treatment initiation. 
As shown in Table 1, patients’ 
characteristics were comparable 
between groups A and B. Each 
group included 86 patients. Median 
age was 61 years for groups A and 
B with a male to female ratio of 
1:1.2 and 1:0.7, respectively. The 
majority of patients had performance 
status ECOG of 1 in groups A and 
B (57% and 51%, respectively). 
The most common histology was 
adenocarcinoma in groups A and 
B (43% and 45%, respectively). 
Sites of distant metastases 
between groups A and B were not 
statistically different except for higher 
liver metastases in group A (Table 2). 
The specific sites of metastases 
in groups A and B were: central 
nervous system (CNS) - 25.6% 
and 27.9%, liver -19.8% and 
9.3%, bone- 30.2%, and 30.2%, 
respectively (Table 2). Group A 
had 7patients (8.1%) vs. B with 4 
patients (4.6%) with isolated liver 
metastases. Patients with non-
squamous cell lung cancer and 
had an EGFR mutation were 6 
patients (6.9%) in group A vs. 5 
patients (5.8%) in group B (P=1.0). 
The median time interval was 
26 and 67 days in groups A and 
B, respectively (Table 3). The 
median overall survival in group A 
was 7 months versus 12 months in 
group B (P =0.04). The 12- month 
overall survival was 36% and 43%, 
in group A and B, respectively 
(P=0.01) [Figure 1]. Group B 
had a favorable overall survival 
when compared to group A with 
unadjusted HR 0.73 (95% CI: 0.52 
-01.01) (P=0.055). After adjustment 
for age, performance status and 
site of metastases, group B had 
a better outcome with HR 0.72 
(95% CI: 0.52 – 0.99) (P=0.05).
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Table 1: Characteristics of patients at the early treatment (group A) and 
delayed treatment (group B). 
Variables Group A Group B P value 
Age at diagnosis, mean (sd) 60.6 (11.5) 61.3 (13.0) 0.71
Race% White(n≠) 96.5 (83) 98.8 (85) 0.31
Gender% Male(n) 45.4 (39) 55.8 (48) 0.17
ECOG * %(n)
0 16.3 (14) 16.3 (14)
0.731 66.3 (57) 59.3 (51)
2 15.1 (13) 20.9 (18)
3 2.3 (2) 3.5 (3)
Histology %(n)
Adenocarcinoma 43.0 (37) 45.4 (39)
0.66
Squamous cell 29.1 (25) 22.1 (19)
Large cell 19.8 (17) 25.6 (22)
Carcinoma NOS† 8.1 (7) 7.0 (6)
≠ n: number of patients, *ECOG: Eastern Cooperative Oncology Group), †NOS: Non 
Otherwise Specified.
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Discussion:
Delaying chemotherapy in the 
adjuvant setting has been shown 
to negatively impact the survival 
outcome in colon and breast 
cancer.9,10 Other reports by Biagi 
et al in meta-analyses showed 
that a 4 weeks delay of adjuvant 
systemic therapy decreased the 
overall survival by 14 % in colon 
cancer13 and 6% lower overall 
survival in breast cancer.14
Data on the impact of treatment 
interval in NSCLC is limited .One 
retrospective report showed that 
time between surgery and initiation 
of adjuvant chemotherapy for more 
than 10 weeks showed no effect 
in survival outcome.11 In another 
study, which included all stages of 
NSCLC, it also showed that interval 
between diagnosis and time to 
treatment did not have any impact 
on survival outcome at any stage.12
Systemic chemotherapy is well 
established as a standard of care 
in stage IV NSCLC and has been 
shown superior to best supportive 
care.15 However, to our knowledge 
there are no studies which have 
evaluated the effect of delayed 
systemic chemotherapy mainly in 
patients with advanced NSCLC. Our 
study was conducted to answer an 
important question for clinicians on 
whether, for a variety of reasons, 
delaying systemic chemotherapy 
in patients with advanced NSCLC 
affects clinical outcome. 
This single institution retrospective 
study showed that delayed systemic 
chemotherapy in patients with 
stage IV NSCLC did not adversely 
impact the overall survival but 
rather interestingly, we observed a 
poorer survival outcome in those 
patients who were treated earlier. 
In the delayed treatment group the 
various reasons which resulted in 
delaying chemotherapy were as 
follows: 40% of the patients had 
to wait to complete their work up 
(staging imaging studies, mutation 
analysis of the tumor, re-biopsies), 
20% of patients required emergency 
surgery (eg., resection of isolated 
brain metastases) whereas only 
one patient had emergency surgery 
for brain metastasis resection 
1.1% in group A, 25% had a delay 
in referral or transfer of care, and 
30% required radiation therapy 
for symptomatic metastases. 
Table 2: Rates of central nervous system (CNS), liver and bone metastases 
between the early treatment (group A) and delayed treatment (group B). 
Sites of 
Metastases %(n) Group A Group B P value
CNS 25.6 (22) 27.9 (24) 0.73
Liver 19.8 (17) 9.3 (8) 0.05
Bone 30.2 (26) 30.2 (26) 1.0
Group A Group B P value
Median time interval (95% CI) 26 (18-35) 66.5 (56-83) <0.001
Median Survival (IQR) 7 (5-10) 12 (9-13) 0.04
12 months overall survival % 36.4 44.3 <0.01
Table 3: Median time interval, median OS, and 12 months OS between the 
early treatment (group A) and delayed treatment (group B).
Figure 1: Kaplan-meier for overall survival between early treatment 
group A and delayed treatment group B. 
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One explanation for our 
observation of a poor outcome in 
the early treatment group would be 
a higher rate of liver metastases. 
Involvement of liver metastases is 
a well known factor that worsens 
the survival of advanced NSCLC.12 
There was no significant difference 
in histology between groups A and B 
in our study, which likely was not a 
confounding factor for the difference 
in overall survival. Furthermore, 
the prognosis of NSCLC has not 
been shown to be significantly 
impacted by the histology subtype.16
Limitations of our study include 
being a single institutional 
retrospective review, small 
population size, and a predominantly 
Caucasian population compared to 
the national data. The majority of our 
study population were Caucasians 
(97%). This is in contrast to the 
CDC report between 1999-2009, 
that black men were found to have 
the greatest risk of developing 
and dying of lung cancer, whereas 
white women had the highest 
risk compared to other races.17
Conclusion
Based on our study, it is 
reassuring to know that delaying 
chemotherapy, if needed (i.e., to 
complete work-up or rehabilitation 
to improve performance status), 
may not adversely affect overall 
survival. Further larger studies are 
required to validate this observation.
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